Nanoparticulate drug delivery : perspectives on the transition from laboratory to market / Vandana Patravale, Prajakta Dandekar and Ratnesh Jain.

Format:

Book

Author/Creator:

Patravale, Vandana.

Contributor:

Dandekar, Prajakta.

Jain, Ratnesh.

Series:

Woodhead Publishing Series in Biomedicine

Woodhead Publishing series in biomedicine, 2050-0289 ; no. 17

Language:

English

Subjects (All):

Drug delivery systems.

Nanoparticles.

Physical Description:

1 online resource (244 p.)

Place of Publication:

Cambridge : Woodhead Pub., 2012.

Language Note:

English

Summary:

Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate sy

Contents:

Cover; Nanoparticulate drug delivery: Perspectives on the transitionfrom laboratory to market; Copyright; Contents; List of figures; List of tables; Foreword; 1 Nanoparticulate systems as drug carriers: the need; 1.1 Introduction: nanoparticles for drug delivery; 1.2 Need: solubility, bioavailability, targeting and more; 1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations; 1.4 References; 2 Nanoparticles as drug carriers; 2.1 Nanoparticles as drug carriers: the scope; 2.2 Nanoparticles as drug delivery carriers

2.3 Application areas for nanoparticulate drug delivery systems2.4 Routes of administration of nanoparticulate drug delivery systems; 2.5 Conclusion; 2.6 References; 3 Characterization techniques for nanoparticulate carriers; 3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers; 3.2 Measuring the size of nanoparticles; 3.3 Zeta potential measurement; 3.4 Characterizing the morphology of the nanoparticles; 3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles; 3.6 Toxicity evaluation of nanoparticles

3.7 Evaluating immunological potential of nanoparticles3.8 References; 4 Nanotoxicology: evaluating toxicity potential of drug-nanoparticles; 4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems; 4.2 In vitro assays for assessing toxicityof nanoparticles; 4.3 In-vivo assays for assessing toxicityof nanoparticles; 4.4 Genotoxicity evaluation; 4.5 References; 5 Regulatory aspects of nanoparticulate drug delivery systems; 5.1 Nanoparticulate drug carriers: the regulatory facet; 5.2 Issues associated with regulating nano-drug delivery systems

5.3 Current approaches for regulating pharmaceutical nanocarriers5.4 References; 6 Clinical trials and industrial aspects; 6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures; 6.2 Case studies: cancer; 6.3 Case studies: other diseases; 6.4 Nanoparticulate drug delivery: an industrial outlook; 6.5 References; 7 Case studies: nano-systems in the market; 7.1 Case studies: performance and market approval; 7.2 Are nano or conventional drug delivery systems a better choice? - a market overview; 7.3 Future perspectives on nanoparticulate drug carriers; 7.4 References

Index

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

ISBN:

1-62870-382-2

1-908818-19-0